Wu Song, Chen Jingyu, Ji Yong, Liu Yuxin, Gao Lu, Chen Guoqiang, Shen Kai, Huang Bin
Department of Cardiothoracic Surgery, The Affiliated Jiangyin People's Hospital of Southeast University Medical College, Jiangyin;
Exp Ther Med. 2011 Nov;2(6):1193-1198. doi: 10.3892/etm.2011.336. Epub 2011 Aug 16.
The hMSH2 gene, a member of the mismatch repair (MMR) pathway, plays a key role in the maintenance of genomic integrity. The common sequence variation in hMSH2, IVS12-6 T>C, has been implicated in cancer risk. However, the results of published studies on this polymorphism remain conflicting. Hence, we conducted a meta-analysis to clarify the role of the hMSH2 IVS12-6 T>C polymorphism in cancer. We performed a comprehensive literature search updated to March 2011 of studies on the associations between the hMSH2 IVS12-6 T>C polymorphism and cancer risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. Thirteen studies involving 7,527 patients and 8,762 control subjects were included in this meta-analysis. The overall results indicated no major influence of the polymorphism on cancer risk. However, stratified analysis by cancer types showed that the hMSH2 IVS12-6 polymorphism increased the risk for non-Hodgkin's lymphomas (heterozygote comparison: OR=1.62; 95% CI 1.06-2.47). When stratified by the source of controls, significant associations were observed in hospital-based populations (heterozygote comparison: OR=1.28; 95% CI 1.02-1.61). These results indicate that the polymorphism of hMSH2, IVS12-6, may cause a different effect in different types of cancers. To draw more comprehensive conclusions, further prospective studies with larger numbers of participants worldwide are required to examine the associations between this polymorphism and cancer risk.
hMSH2基因是错配修复（MMR）通路的成员之一，在维持基因组完整性方面发挥关键作用。hMSH2基因的常见序列变异IVS12-6 T>C与癌症风险有关。然而，已发表的关于这种多态性的研究结果仍然相互矛盾。因此，我们进行了一项荟萃分析，以阐明hMSH2基因IVS12-6 T>C多态性在癌症中的作用。我们对截至2011年3月的关于hMSH2基因IVS12-6 T>C多态性与癌症风险关联的研究进行了全面的文献检索。采用优势比（OR）和95%置信区间（CI）来评估关联强度。本荟萃分析纳入了13项研究，涉及7527例患者和8762例对照。总体结果表明，该多态性对癌症风险没有重大影响。然而，按癌症类型进行分层分析显示，hMSH2基因IVS12-6多态性增加了非霍奇金淋巴瘤的风险（杂合子比较：OR=1.62；95%CI 1.06-2.47）。按对照来源进行分层时，在基于医院的人群中观察到显著关联（杂合子比较：OR=1.28；95%CI 1.02-1.61）。这些结果表明，hMSH2基因IVS12-6的多态性可能在不同类型的癌症中产生不同的影响。为了得出更全面的结论，需要在全球范围内进行更多参与者的进一步前瞻性研究，以检验这种多态性与癌症风险之间的关联。
